MARSEILLE, France–(BUSINESS WIRE)–Regulatory Information:
Innate Pharma SA (OTC:) (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Firm), immediately introduced that the Firm will maintain a convention name on Thursday, September 12, 2024, at 2 p.m. CEST / 8 a.m. EDT, to provide an replace on enterprise progress through the first half of 2024.
Contributors through the name shall be:
- Hervé Brailly, Chief Government Officer
- Sonia Quaratino, Government Vice President, Chief Medical Officer
- Yannis Morel, Government Vice President, Chief Working Officer
- Frédéric Lombard, Senior Vice President, Chief Monetary Officer
- Arvind Sood, Government Vice President, President of US Operations
Particulars for the Digital Occasion
The reside webcast shall be accessible on the following hyperlink:
https://occasions.q4inc.com/attendee/127231232
Contributors may additionally be a part of by way of phone utilizing the next registration hyperlink: https://registrations.occasions/direct/Q4I953384196
This info can be discovered on the Traders part of the Innate Pharma web site, www.innate-pharma.com. A replay of the webcast shall be accessible on the Firm web site for 90 days following the occasion.
About Innate Pharma
Innate Pharma S.A. is a world, clinical-stage biotechnology firm growing immunotherapies for most cancers sufferers. Its modern strategy goals to harness the innate immune system via therapeutic antibodies and its ANKET ® (Antibody-based NK cell Engager Therapeutics) proprietary platform.
Innate’s portfolio contains lead proprietary program lacutamab, developed in superior type of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca (NASDAQ:) in non-small cell lung most cancers, in addition to ANKET ® multi-specific NK cell engagers to handle a number of tumor varieties.
Innate Pharma is a trusted companion to biopharmaceutical corporations reminiscent of Sanofi (NASDAQ:) and AstraZeneca, in addition to main analysis establishments, to speed up innovation, analysis and growth for the advantage of sufferers.
Headquartered in Marseille, France with a US workplace in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq within the US.
Be taught extra about Innate Pharma at www.innate-pharma.com and comply with us on LinkedIn and X.
Details about Innate Pharma shares
ISIN code |
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking info and danger elements
This press launch incorporates sure forward-looking statements, together with these throughout the that means of the Non-public Securities Litigation Reform Act of 1995. The usage of sure phrases, together with consider, potential, anticipate and can and related expressions, is meant to determine forward-looking statements. Though the corporate believes its expectations are primarily based on affordable assumptions, these forward-looking statements are topic to quite a few dangers and uncertainties, which may trigger precise outcomes to vary materially from these anticipated. These dangers and uncertainties embrace, amongst different issues, the uncertainties inherent in analysis and growth, together with associated to security, development of and outcomes from its ongoing and deliberate medical trials and preclinical research, evaluate and approvals by regulatory authorities of its product candidates, the Firm’s commercialization efforts and the Firm’s continued means to lift capital to fund its growth. For an extra dialogue of dangers and uncertainties which may trigger the corporate’s precise outcomes, monetary situation, efficiency or achievements to vary from these contained within the forward-looking statements, please confer with the Threat Elements (Facteurs de Risque”) part of the Common Registration Doc filed with the French Monetary Markets Authority (AMF), which is out there on the AMF web site http://www.amf-france.org or on Innate Pharma’s web site www.innate-pharma.com, and public filings and studies filed with the U.S. Securities and Change Fee (SEC), together with the Firm’s Annual Report on Kind 20-F for the 12 months ended December 31, 2023, and subsequent filings and studies filed with the AMF or SEC, or in any other case made public, by the Firm.
This press launch and the data contained herein don’t represent a proposal to promote or a solicitation of a proposal to purchase or subscribe to shares in Innate Pharma in any nation.
View supply model on businesswire.com: https://www.businesswire.com/information/dwelling/20240904420893/en/
For extra info, please contact:
Traders
Innate Pharma
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
[email protected]
Media Relations
NewCap
Arthur Rouillé
Tel.: +33 (0)1 44 71 00 15
[email protected]
Supply: Innate Pharma SA